Your browser doesn't support javascript.
loading
Tumour-agnostic drugs in paediatric cancers.
Chisholm, Julia C; Carceller, Fernando; Marshall, Lynley V.
Afiliação
  • Chisholm JC; Paediatric and Adolescent Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK. julia.chisholm@rmh.nhs.uk.
  • Carceller F; Paediatric and Adolescent Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.
  • Marshall LV; Paediatric and Adolescent Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.
Br J Cancer ; 122(10): 1425-1427, 2020 05.
Article em En | MEDLINE | ID: mdl-32161367
The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pediatria / Proteínas de Fusão Oncogênica / Neoplasias Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pediatria / Proteínas de Fusão Oncogênica / Neoplasias Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article